An Overview of the MONARCH and NeoMONARCH Trials in Breast Cancer
March 12th 2017Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the ongoing MONARCH and neoMONARCH studies in breast cancer.
Watch
Healthcare Utilization and Costs Remain High for TNBC, Study Shows
March 12th 2017According to a retrospective 4.5-year study of patients who had commercial and Medicare supplemental coverage, healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer.
Read More
PARP Inhibitors Likely This Year's Breakthrough In Breast Cancer Management
March 12th 2017Kimberly Blackwell, MD, discusses the results of the recent phase III OLYMPIAD trial, which showed olaparib (Lynparza) improved progression-free survival (PFS) versus standard chemotherapy in patients with <em>BRCA</em>-positive breast cancer.
Read More
High Expectation for Precision Medicine May Foil Genomic Medicine, Expert Says
March 11th 2017Larry Norton, MD, says the so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.
Read More
Ribociclib Results Promising for Elderly Patients With HR+/HER2- Breast Cancer
March 10th 2017The addition of the CDK4/6 inhibitor ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Read More
Eribulin/Pembrolizumab Combination Active in TNBC
March 10th 2017Combining eribulin with pembrolizumab for patients with metastatic triple-negative breast cancer demonstrated promising objective response rates, including a complete response, according to findings from a phase Ib/II study presented at the 2017 Miami Breast Cancer Conference.
Read More
The Link Between Circulating Tumor Cells and Survival Outcomes in Breast Cancer
March 10th 2017Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the link between circulating tumor cells and survival outcomes in metastatic breast cancer.
Watch
Ruxolitinib Demonstrates Safety, Efficacy in Myelofibrosis, Expanded Access Trial Confirms
February 28th 2017Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.
Read More
Arginine-Depleting Agent Added to Standard Therapy Shows Promise in Pancreatic Cancer
February 9th 2017The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel and gemcitabine has encouraging activity in patients with advanced pancreatic adenocarcinoma while demonstrating minimal additional toxicity over that with cytotoxic therapy alone.
Read More
MPC Treatment Costs Lower with Nab-Paclitaxel/Gemcitabine Than FOLFIRINOX
February 8th 2017<span style="font-size:12px">Treatment administration and supportive care costs were significantly higher for patients with metastatic pancreatic cancer who were treated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine.</span>
Read More
Nanoliposomal Irinotecan Regimen Improves OS in Pancreatic Cancer
February 8th 2017Overall survival was improved and disease progression was slowed in patients with metastatic pancreatic ductal adenocarcinoma when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.
Read More
CCR2 Blockade Holds Clinical Promise in Advanced or Metastatic Pancreatic Cancer
January 25th 2017CCX872-B, a potent, selective oral inhibitor of CCR2, added to FOLFIRINOX was associated with a tumor control rate of 78% at week 12 in a single-arm study of patients with locally advanced or metastatic pancreatic cancer.
Read More
Chemotherapy/Immunotherapy Regimen Active in Treated, Untreated Pancreatic Cancer
January 25th 2017Encouraging clinical activity with limited toxicity in patients with metastatic pancreatic cancer will lead to further evaluation of nivolumab plus nab-paclitaxel with gemcitabine, investigators reported at the Gastrointestinal Cancers Symposium in San Francisco.
Read More